Replies to post #218616 on Biotech Values

[biomaven0]

>>makes RT002 competitive with even the longest-acting CGRP compounds in terms of cost and convenience.

But not in efficacy. Botox is borderline efficacious (which makes trials very tough) and the CGRP's work really well. There is some argument that Botox in fact works via decreasing CGRP, and if that is correct I'm not sure there will be patients that fail a CGRP and work with a Botox-type drug.